Home > List All Publishers > La Merie Publishing

La Merie Publishing

La Merie Business Intelligence is focused on Research and Development in the Biopharmaceutical Industry. La Merie provides information about biopharmaceutical R&D and competitive intelligence by Publishing, Consultancy and its Biotech Portal PipelineReview.com. The information is retrieved from La Merie’s in house R&D database, news portal and direct as well as desktop searches. La Merie has a focus on Biologics, including antibodies, proteins, peptides, vaccines, RNA, DNA and cell therapy.

La Merie publishes Competitor Analysis Reports, Brief Reports and Full Reports. The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies.
The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as a la carte or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are elaborated by independent analysts of La Merie Business Intelligence. Brief Reports on Target Pipelines include assessment of the scientific as well as business perspective of new targets. Full reports provide in-depth analysis of product portfolios, R&D pipelines, competitive environment and a critical assessment of the pipeline perspective.

List of reports from La Merie Publishing

Antibody Pipeline Database: 1-Year Subscription 11/1/2010 \| published by: La Merie Publishing ... or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D ... \| more...	$1,638.00
Antibody Technology Companies 2010 11/1/2010 \| published by: La Merie Publishing ... The report describes and analyzes the market size of therapeutic monoclonal antibodies and Fc-fusion proteins in 2009. Characteristics of approved antibody-based products regarding identification, construction and manufacturing are evaluated as a basis for relevant antibody ... \| more... Search inside this report	$1,394.00
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis 9/1/2011 \| published by: La Merie Publishing ... and products in R&D. A comprehensive analysis of the state of the art and key trends guides the reader through this complex subject. Stakeholders in the field of antibody-drug conjugates are analysed and their contribution ... \| more... Search inside this report	$2,600.00
Brief Report: Interleukin-17 (IL-17R) and IL-17 Receptor Antagonists 2/1/2010 \| published by: La Merie Publishing ... IL-17R to treat inflammatory and autoimmune diseases are discussed as of February 2010. A total of three different antibodies are in mid- and late stage clinical development, with others in early clinical, non-clinical or preclinical ... \| more... Search inside this report	$697.00
Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis 8/1/2009 \| published by: La Merie Publishing ... pipeline for each of the coagulation factors used for systemic and topical administration. Companies active in the therapeutic coagulation business are evaluated and the strengths, weaknesses, opportunities and threats (SWOT) in their R&D pipeline benchmarked ... \| more... Search inside this report	$3,454.00
Coagulation Factors 2011 - who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis 10/11/2011 \| published by: La Merie Publishing ... R&D pipelines as of October 2011. The authors analyze and assess the target pipeline for each of the coagulation factors for haemophilia and work out the target profiles of development projects. A market research study ... \| more... Search inside this report	$3,258.00
Competitor Analysis: Adenosine Receptor Agonists & Antagonists 4/1/2011 \| published by: La Merie Publishing ... on the adenosine receptor subtype (A1, A2, A3) and on stimulation or blockade, molecules find use for treatment of diseases including glaucoma, dry eye, cardiac imaging, asthma, psoriasis, rheumatoid arthritis as well as Parkinson’s diasese. ... \| more... Search inside this report	$287.00
Competitor Analysis: Adenosine Receptor Agonists & Antagonists 5/4/2008 \| published by: La Merie Publishing ... clinical development of Adenosine Receptor Agonists & Antagonistsas of May 2008. The report includes a compilation of current active projects in research and development of agonists and antagonists of the adenosine receptor subtypes 1, 2A, ... \| more... Search inside this report	$175.00
Competitor Analysis: Alzheimer’s Disease Antibodies 7/6/2008 \| published by: La Merie Publishing ... companies active in the field of new antibodies for passive immunotherapy of Alzheimer’s disease Wyeth, Elan, Pfizer, Roche and many others. The report includes a compilation of current active projects in research and development of ... \| more... Search inside this report	$140.00
Competitor Analysis: Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's disease 3/28/2009 \| published by: La Merie Publishing ... as of March 2009. Amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) is a rapidly progressing, motor neuron disease characterized by the gradual degeneration and death of motor neurons. When muscles in the diaphragm ... \| more... Search inside this report	$275.00
Competitor Analysis: Anthrax Vaccines and Therapeutics 5/1/2010 \| published by: La Merie Publishing ... Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and ... \| more... Search inside this report	$312.00
Competitor Analysis: Antibody Therapy of Inflammatory and Autoimmune Diseases 12/1/2010 \| published by: La Merie Publishing ... ulcerative colitis, multiple sclerosis, asthma and other autoimmune diseases as of December 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the ... \| more... Search inside this report	$1,184.00
Competitor Analysis: Antibody-Drug Conjugates (ADC) 12/1/2011 \| published by: La Merie Publishing ... Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and ... \| more... Search inside this report	$669.00
Competitor Analysis: Antihypertensives 6/13/2008 \| published by: La Merie Publishing ... information about the market size of the largest drug class for treatment of arterial hypertension, i.e. angiotensin receptor blockers. Among the companies active in the field of new antihypertensives are Sanofi-Aventis, Daiichi-Sankyo, Bristol-Myers Squibb, GlaxoSmithKline, ... \| more... Search inside this report	$410.00
Competitor Analysis: Anti-Infective Antibodies 11/1/2011 \| published by: La Merie Publishing ... as of November 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be ... \| more... Search inside this report	$1,086.00
Competitor Analysis: Anti-Infective Antibodies 7/1/2010 \| published by: La Merie Publishing ... as of July 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be ... \| more... Search inside this report	$1,011.00
Competitor Analysis: Anti-Infective Peptides 12/1/2011 \| published by: La Merie Publishing ... the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online ... \| more... Search inside this report	$401.00
Competitor Analysis: Anti-Obesity Peptides and Biologics 2/1/2012 \| published by: La Merie Publishing ... 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. The database also contains information about discontinued projects. Credentials to ... \| more... Search inside this report	$262.00
Competitor Analysis: Antithrombotics 8/5/2008 \| published by: La Merie Publishing ... includes 2007 sales figures of the major products for low-molecular weight heparins (LMWH), specific indirect F. Xa inhibitor, direct thrombin inhibitors, antithrombin III, activated protein C (aPC) and inhibitors of platelet aggregation via the ADP ... \| more... Search inside this report	$685.00
Competitor Analysis: Antiviral Antibodies 7/13/2008 \| published by: La Merie Publishing ... respiratory syncytial virus (RSV), human immunedeficiency virus (HIV), influenza, rabies, smallpox and West Nile virus. Among the companies active in the field are mostly biotech companies. The report includes a compilation of current active projects ... \| more... Search inside this report	$275.00
Competitor Analysis: Attention-Deficit Hyperactivity Disorder (ADHD) 3/15/2009 \| published by: La Merie Publishing ... is a common and highly heritable neurodevelopmental psychiatric disease. It is also an indication for commercially successful drugs. The major ADHD drugs posted 2008 sales of US$ 3.9 bln. The current generation of ADHD treatments ... \| more... Search inside this report	$275.00
Competitor Analysis: Aurora Kinase Inhibitors 5/23/2008 \| published by: La Merie Publishing ... targeting aurora A, B and C kinase (aurora pan-kinase), aurora A and B kinase, aurora A kinase, aurora B kinase, not specified aurora kinase inhibitors and dual as well as multi-target aurora kinase with e.g. ... \| more... Search inside this report	$175.00
Competitor Analysis: Aurora Kinase Inhibitors 6/1/2009 \| published by: La Merie Publishing ... tumor growth, is highly regulated to ensure accurate and equal segregation of genetic materials from parent cells to daughter cells. Main effectors of this process are mitotic spindles and centrosomes.157 Disruption of the process results ... \| more... Search inside this report	$250.00
Competitor Analysis: B7 - CD28/CTLA-4 Pathway 3/1/2010 \| published by: La Merie Publishing ... or cancer as of March 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database ... \| more... Search inside this report	$274.00
Competitor Analysis: Bcr-Abl and Src Kinase Inhibitors 7/1/2009 \| published by: La Merie Publishing ... Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two ... \| more...	$840.00

< prev 1 2 3 4 5 6 next >